EVIDENCE MAP OF COSTS STUDIES IN CYSTIC FIBROSIS SINCE 2000
Author(s)
Martin A
Crystallise Ltd., East Tilbury, UK
Presentation Documents
OBJECTIVES: To create an evidence map of studies reporting the direct and indirect costs associated with cystic fibrosis, and the geographical settings in which these studies were conducted. METHODS: We searched the heoro.com database (www.heoro.com) for costs studies in cystic fibrosis published between and costs reported across the range of geographical locations and interventions. We presented the findings as an evidence map. RESULTS: We found a total of abstracts. Of these, reported direct costs from countries and seven reported indirect costs from five countries. The most common setting was the United States, with Nine studies were reviews of the international literature. Fourteen studies reported costs of healthcare in general. Specific interventions studied included prenatal or neonatal screening (18 abstracts), antibiotics for respiratory infections (usually Pseudomonas, 11 abstracts), rhDNase and lung transplants and associated treatments (4 abstracts each). Twenty five abstracts were economic models and CONCLUSIONS: As with many diseases, there is a relative lack of published data on indirect costs of cystic fibrosis, and two-thirds of studies reporting cost data were from just four jurisdictions: Australia, Canada, the UK and the USA.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRS25
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders